|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | IFNγ and B7-H1 in the immunology of mesenchymal stem cells显示文摘 | Pranela Rameshwar | 2008 | Cell Research2008，18，8： | 2 |
| 2 | Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells显示文摘 | Jacqueline M. Park Jessian L. Munoz Brian Wong Won Sarah A. Bliss Steven J. Greco Shyam Patel Mustapha Kandouz Pranela Rameshwar | 2012 | Cancer Letters2012，，： | 1 |
| 3 | Distinct roles of glycogen synthase Kinase (GSK)-3c:andGSK-313 in mediating car- diomyocyte differentiation in murine bone Marrow-derived mesenchymal stem cells显示文摘 | Jaeyeaon C Pranela R Junichi S | 2009 | The Journal of Biological Chem- istry2009，284，36： | 1 |
| 4 | Comparative Evaluation of Human Mesenchymal Stem Cells of Fetal (Wharton’s Jelly) and Adult (Adipose Tissue) Origin during Prolonged In Vitro Expansion: Considerations for Cytotherapy显示文摘 | I. Christodoulou F. N. Kolisis D. Papaevangeliou V. Zoumpourlis Pranela Rameshwar | 2013 | Stem Cells International2013，，： | 1 |
| 5 | The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential显示文摘 | Tammy A. Castro Marion C. Cohen Pranela Rameshwar | 2005 | Clinical & Experimental Metastasis2005，，8： | 1 |
| 6 | Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis显示文摘 | Indroneil Mukerji Shakti H. Ramkissoon Kavitha K. R. Reddy Pranela Rameshwar | 2005 | Journal of Neuro - Oncology2005，，2： | 1 |
| 7 | Distinct Roles of Glycogen Synthase Kinase (GSK)-3ct and GSK-313 in Mediating Cardiomyocyte Differentiation in Murine Bone Marrow-derived Mesenchymal Stem Cells 显示文摘 | Jaeyeaon Cho Rameshwar Pranela | 2009 | Journal of Biological Chemistry2009，284，36： | 1 |
| 8 | Immunological properties of mesenchymal stem cells and clinical implications显示文摘 | Shyam A. Patel Lauren Sherman Jessian Munoz Pranela Rameshwar | 2008 | Archivum Immunologiae et Therapiae Experimentalis2008，，1： | 1 |
| 9 | Immunological properties of mesenchymal stem cells and clinical implications显示文摘 | Shyam A. Patel Lauren Sherman Jessian Munoz Pranela Rameshwar | 2008 | Archivum Immunologiae et Therapiae Experimentalis2008，，1： | 1 |
| 10 | Hematopoietic failure after hemorrhagic shock is mediated partially through mesenteric lymph显示文摘 | Devashish J. Anjaria Pranela Rameshwar Edwin A. Deitch Da-Zhong Xu Charles A. Adams Raquel M. Forsythe Justin T. Sambol Carl J. Hauser David H. Livingston | 2001 | Critical Care Medicine2001，，9： | 1 |
| 11 | Isolation and characterization of mesenchymal stem cells in orthopaedics and the emergence of compact bone mesenchymal stem cells as a promising surgical adjunct显示文摘The potential clinical and economic impact of mesenchymal stem cell(MSC)therapy is immense.MSCs act through multiple pathways:(1)as“trophic”cells,secreting various factors that are immunomodulatory,anti-inflammatory,antiapoptotic,proangiogenic,proliferative,and chemoattractive;(2)in conjunction with cells native to the tissue they reside in to enhance differentiation of surrounding cells to facilitate tissue regrowth.Researchers have developed methods for the extraction and expansion of MSCs from animal and human tissues.While many sources of MSCs exist,including adipose tissue and iliac crest bone graft,compact bone(CB)MSCs have shown great potential for use in orthopaedic surgery.CB MSCs exert powerful immunomodulatory effects in addition to demonstrating excellent regenerative capacity for use in filling boney defects.CB MSCs have been shown to have enhanced response to hypoxic conditions when compared with other forms of MSCs.More work is needed to continue to characterize the potential applications for CB MSCs in orthopaedic trauma. | Albert Anastasio Marina Gergues Michael S Lebhar Pranela Rameshwar Joseph Fernandez-Moure | 2020 | World Journal of Stem Cells2020，12，11： | 0 |
| 12 | Would cancer stem cells affect the future investment in stem cell therapy?显示文摘The common goal within the overwhelming interests in stem cell research is to safely translate the science to patients. Although there are various methods by which this goal can be reached, this editorial emphasizes the safety of mesenchymal stem cell(MSC) transplant and possible confounds by the growing information on cancer stem cells(CSCs). There are several ongoing clinical trials with MSCs and their interactions with CSCs need to be examined. The rapid knowledge on MSCs and CSCs has now collided with regards to the safe treatment of MSCs. The information discussed on MSCs can be extrapolated to other stem cells with similar phenotype and functions such as placenta stem cells. MSCs are attractive for cell therapy, mainly due to reduced ethical concerns, ease in expansion and reduced ability to be transformed. Also, MSCs can exert both immune suppressor and tissue regeneration simultaneously. It is expected that any clinical trial with MSCs will take precaution to ensure that the cells are not transformed. However, going forward, the different centers should be aware that MSCs might undergo oncogenic events, especially as undifferentiated cells or early differentiated cells. Another major concern for MSC therapy is their ability to promote tumor growth and perhaps, to protect CSCs by altered immune responses. These issues are discussed in light of a large number of undiagnosed cancers. | Pranela Rameshwar | 2012 | World Journal of Experimental Medicine2012，2，2： | 0 |
| 13 | Microenvironment at tissue injury, a key focus for efficient stem cell therapy: A discussion of mesenchymal stem cells显示文摘Stem cell therapy is not a new field, as indicated by the success of hematopoietic stem cell reconstitution for various hematological malignancies and immune-mediated disorders. In the case of tissue repair, the major issue is whether stem cells should be implanted, regardless of the type and degree of injury. Mesenchymal stem cells have thus far shown evidence of safety, based on numerous clinical trials, particularly for immune-mediated disorders. The premise behind these trials is to regulate the stimulatory immune responses negatively. To apply stem cells for other disorders, such as acute injuries caused by insults from surgical trauma and myocardial infarction, would require other scientific considerations. This does not imply that such injuries are not accompanied by immune responses. Indeed, acute injuries could accompany infiltration of immune cells to the sites of injuries. The implantation of stem cells within a milieu of inflammation will establish an immediate crosstalk among the stem cells, microenvironmental molecules, and resident and infiltrating immune cells. The responses at the microenvironment of tissue injury could affect distant and nearby organs. This editorial argues that the microenvironment of any tissue injury is a key consideration for effective stem cell therapy. | Pranela Rameshwar | 2009 | World Journal of Stem Cells2009，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员